BC007
/ Berlin Cures
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
80
Go to page
1
2
3
4
November 18, 2024
BLOC: To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
(clinicaltrials.gov)
- P2 | N=119 | Completed | Sponsor: Berlin Cures GmbH | Active, not recruiting ➔ Completed
Trial completion • Novel Coronavirus Disease
July 09, 2024
BLOC: To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
(clinicaltrials.gov)
- P2 | N=119 | Active, not recruiting | Sponsor: Berlin Cures GmbH | Trial completion date: May 2025 ➔ Nov 2024 | Trial primary completion date: Apr 2025 ➔ Aug 2024
Trial completion date • Trial primary completion date • Novel Coronavirus Disease
May 07, 2024
Persistence of autoantibodies directed against the beta-1-adrenoceptor in patients with heart failure after treatment with BC 007 (Rovunaptabin). Results of a phase IIa study.
(HEART FAILURE 2024)
- "In pts with moderate to severe heart failure in whom AABs directed against B1-A have been detected, it is very likely that these will not disappear spontaneously. BC 007 is highly effective in neutralizing AABs directed against B1-A. The recurrence of AABs after several months of a single treatment can effectively be prevented by a second dose."
Clinical • P2a data • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure
April 16, 2024
BLOC: To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
(clinicaltrials.gov)
- P2 | N=114 | Active, not recruiting | Sponsor: Berlin Cures GmbH | Recruiting ➔ Active, not recruiting
Enrollment closed • Novel Coronavirus Disease
March 04, 2024
Persistence of autoantibodies directed against the beta-1-adrenoceptor in patients with heart failure after treatment with BC 007 (Rovunaptabin). Results of a phase IIa study.
(HEART FAILURE 2024)
- No abstract available
Clinical • P2a data • Cardiovascular • Congestive Heart Failure • Heart Failure
November 15, 2023
BLOC: To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
(clinicaltrials.gov)
- P2 | N=114 | Recruiting | Sponsor: Berlin Cures GmbH | Trial completion date: Nov 2024 ➔ May 2025 | Trial primary completion date: Oct 2024 ➔ Apr 2025
Trial completion date • Trial primary completion date • Novel Coronavirus Disease
July 29, 2023
"Kümmern Sie sich um #Impfschäden! Kümmern Sie sich um #Impfnebenwirkungen! Kümmern Sie sich um #PostVac-Betroffene! Kümmern Sie sich um #LongCovid-Betroffene! Kümmern Sie sich um #LongCovidKids! Kümmern Sie sich um #MECFS-Betroffene! Kümmern Sie sich um #BC007 von @BerlinCures!"
(@B_A_f_H_)
Novel Coronavirus Disease
July 27, 2023
"The @EMA_News is not doing anything to accelerate the approval process. Therefore the #BC007 approval will take years!"
(@TimoStrotmann)
July 27, 2023
"I hope so, there must be an emergency approval for bc007 against long covid"
(@Aiioo156Aiioo)
Novel Coronavirus Disease
July 14, 2023
"@Dr_B_Hohberger AAK und bc007 @KraterMartin Blutzellverformung @maidoc im Bezug auf mcas"
(@SunnyDayYeah)
June 20, 2023
BLOC: To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
(clinicaltrials.gov)
- P2 | N=114 | Recruiting | Sponsor: Berlin Cures GmbH
New P2 trial • Novel Coronavirus Disease
June 09, 2023
"Have you looked into the drug bc 007 at all via berlin cures?"
(@Bradgolf1216)
May 15, 2023
"BC 007!"
(@CrissieT6)
April 11, 2023
"Hello, I hope you can pay attention to BC007, a small molecule based on GCPR-aab theory, which really shows great potential for treating longcovid!"
(@lingtian888888)
Novel Coronavirus Disease
April 08, 2023
"@BayerKarriere @BPI_Pharma @BMG_Bund @BMZ_Bund @BMUV @BMBF_Bund @BMFSFJ @DIEZEIT @TAG24 @StZ_NEWS @AstraZeneca @novartis #BC007 #Immunadsorption #HELP #Apherese #IHHT #HBOT #Medikamentenmangel #Medizinbrennt #HILFE #Antiviral #chronicillness #FroheOstern #ableist #BringBackMasks"
(@FrauSausNRW)
April 03, 2023
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
(clinicaltrials.gov)
- P2 | N=30 | Completed | Sponsor: Berlin Cures GmbH | Active, not recruiting ➔ Completed
Trial completion • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure
April 03, 2023
"Besser wenn wir betroffene selbst Mikroskop kaufen, als auf solche "Forscher" warten.Nach 60Jahren MECFS Gesgcichte und diese Forscher haben viel weniger Ahnung, als die Betroffene...Geben Sie mir diese 22,5 millionen besser verschwende ich auf BC007 als solche "STUDIEN""
(@Kovek88)
March 24, 2023
"BC007 from @BerlinCures need a push! @Europarl_EN and @EMA_News ist totally incompetent!"
(@MartinWirone)
March 15, 2023
"@BayerKarriere @BPI_Pharma @BMG_Bund @BMZ_Bund @BMUV @BMBF_Bund @BMFSFJ @DIEZEIT @TAG24 @StZ_NEWS @AstraZeneca #BC007 #Immunadsorption #HELP #Aphererese #IHHT #HBOT #Medikamentenmangel #Medizinbrennt #HILFE"
(@FrauSausNRW)
February 08, 2023
"A bit of BC007 might be nice."
(@tammbrant)
February 05, 2023
"🪄Looks like BC007 💕🤩💖✨ Danke für Deine Arbeit, Faraz!!! Das wird eine super Kampagne!"
(@A_n_y____)
January 18, 2023
"„Die @EMA_News und das @bfarm geben Phase 3 Studie für BC007 frei“ „Riesen Erfolg die Discover Studie in Erlangen ist Abgeschlossen und Recover soll eventuell in 2034 starten“ „Longcovid Experte Prof Kleinschnitz tritt für die AFD zur Bundestagswahl an“ Jetzt seid ihr dran!"
(@MartinWirone)
P3 data • Novel Coronavirus Disease
January 15, 2023
"BC007!"
(@MaryMitsh)
January 15, 2023
"Sie empfehlen #bc007 auf Twitter und verhindern seit 1,5 Jahren dessen Zulassung als Minister???? #schwereschuld #postcovid #mecfs Ist das Satire???"
(@dornroesche)
Novel Coronavirus Disease
January 14, 2023
"Look at bc007 and dysautonomia"
(@BlackCa92876007)
1 to 25
Of
80
Go to page
1
2
3
4